Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary shares, par value 0.002 GBP per share
-
Shares outstanding
-
147,336,360
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
70,339,619
-
Shares change
-
+3,445,275
-
Total reported value, excl. options
-
$435,403,089
-
Value change
-
+$25,413,534
-
Put/Call ratio
-
442%
-
Number of buys
-
19
-
Number of sells
-
-11
-
Price
-
$6.19
Significant Holders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) as of Q2 2023
49 filings reported holding CNTA - Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share as of Q2 2023.
Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70,339,619 shares
of 147,336,360 outstanding shares and own 48% of the company stock.
Largest 10 shareholders include Medicxi Ventures Management (Jersey) Ltd (19,963,157 shares), GENERAL ATLANTIC, L.P. (9,681,818 shares), BVF INC/IL (9,423,215 shares), EcoR1 Capital, LLC (5,618,779 shares), Vida Ventures Advisors, LLC (3,931,818 shares), OUP Management Co., LLC (2,937,615 shares), FMR LLC (2,787,194 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,363,211 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2,250,000 shares), and Point72 Asset Management, L.P. (2,011,388 shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.